Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies
Information source: University Hospital, Bordeaux
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Dementia With Lewy Bodies
Intervention: Imaging with IBVM (Other); Imaging with DATSCAN (Other); neuropsychological evaluation (Behavioral)
Phase: N/A
Status: Completed
Sponsored by: University Hospital, Bordeaux Official(s) and/or principal investigator(s): Michèle ALLARD, Pr, Principal Investigator, Affiliation: University Hospital, Bordeaux
Summary
The general aim of this research project is to determine the relationships between
alterations of central cholinergic (ACh) and dopaminergic (DA) systems and neurobehavioral
features of dementias with Lewy bodies (DLB).
Both clinical and neurochemical data support the view that DLB is not a homogeneous entity
and it can be hypothesized that differential alterations of central ACh systems (i. e.
anterior vs posterior vs striatal interneurons) in association or not with a DA
nigrostriatal dysfunction could partly support the clinical heterogeneity observed in this
disease. ACh in vivo imaging has been relatively underutilized to date and to our knowledge
only on the postsynaptic side. Furthermore, ACh/DA interactions and their relationships with
the symptomatology of DLB and related pathologies (PDD) had never been investigated.
Clinical Details
Official title: In Vivo SPECT Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies: Applying in Diagnostic and Identification of Pathological Subtypes.
Study design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research
Primary outcome: Binding Potential (BP) quantification of each radioligand
Secondary outcome: Ratio dopaminergic system/cholinergic system Binding Potential
Detailed description:
Neurochemical investigations and observations suggest a crucial physiopathological role of
central ACh systems in dementias with Lewy bodies (DLB). Alterations of cholinergic neurons
could be involved in the general cognitive decline (central feature) but also in fluctuating
attentional performances and rapid eye movement sleep disorder as it was shown in thalamus.
Post synaptic in vivo SPECT imaging recently demonstrated an increase in muscarinic
receptors in DLB patients in the occipital cortex that could be associated with the
visuospatial dysfunction often reported in DLB or even in visual hallucinations. From a
pharmacological point of view, the involvement of ACh systems in DLB is confirmed by the
consistently reported efficacy of cholinesterase inhibitor therapy, considered as greater
than in AD.
Concerning DA systems, presynaptic in vivo SPECT imaging studies of DA transporter have
shown a decreased striatal uptake in DLB patients, different when compared with Parkinson's
disease patients or Alzheimer's disease patients.
Strategy, procedure In this project we will use for the first time in vivo molecular imaging
of presynaptic molecular target of ACh systems (VAChT) with [123I]-iodobenzovesamicol and of
DA systems (DAT) with DATSCAN in order to better analyse the link between neurobehavioral
profiles of patients and a differential alteration of ACh/DA systems in DLB.
Eligibility
Minimum age: 18 Years.
Maximum age: 90 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients: man or woman probable DLB, with and without extrapyramida syndrome
- Healthy subjects: man or woman with no neuropsychiatric disorders
Exclusion Criteria:
- Diagnostic or therapeutic irradiation during the 12 months before SPECT imaging
- Age less than 18 and more than 90
- Iodine sensibility
- Brain-vascular disease, severe brain injury, type I and II diabetes mellitus, thyroid
dysfunction, chronic alcoholism
- Pregnant and breast feeding women, women in age to procreate
- Impossibility to undergo MRI study (pace-maker, claustrophobia)
- Persons under guardianship, outside state to express their assent or in emergency
situation
- Healthy subjects: cognitive impairment, dementia
Locations and Contacts
Groupe Hospitalier Pellegrin - C.H.U. de Bordeaux, Bordeaux 33076, France
Additional Information
Starting date: May 2009
Last updated: August 20, 2014
|